# US 2003/0229204 A1 · PCG-1, a novel brown fat PPARgamma coactivator

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229204 A1
- Document ID: US20030229204A1
- Status: Published application
- Kind: A1
- Application number: 10/439,799
- Filed: 2003-05-16
- Published: 2003-12-11
- Earliest claimed: 1997-05-30
- Assignees: Dana-Farber Cancer Institute, Inc.
- Inventors: Bruce M. Spiegelman; Pere Puigserver; Zhidan Wu; Guillaume Adelmant
- Web page: https://patentgrep.com/patent/US20030229204A1

## CPC

- C07K 14/5759: {Products of obesity genes, e.g. leptin, obese (OB), tub, fat}
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- C07K 14/4702: {Regulators; Modulating activity}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2217/075: inducing loss of function, i.e. knock out
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2799/026: where the vector is derived from a baculovirus
- G01N 2500/00: Screening for compounds of potential therapeutic value
- Y10S 435/81: Packaged device or kit
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

## Claims

### Claim 1

An isolated nucleic acid molecule comprising a nucleotide sequence encoding PGC-1 or a portion thereof.

### Claim 2

An isolated nucleic acid molecule comprising a nucleotide sequence encoding a protein or a portion thereof, wherein the protein or portion thereof comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 such that the protein or portion thereof maintains the ability to modulate one or more of the following biological activities: UCP expression, thermogenesis in adipose cells, differentiation of adipose cells, and insulin sensitivity of adipose cells.

### Claim 3 (depends on 2)

The isolated nucleic acid molecule of claim 2, wherein the protein comprises an amino acid sequence at least about 60% homologous to the entire amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5.

### Claim 4 (depends on 2)

The isolated nucleic acid molecule of claim 2, wherein the portion of the protein comprises one or more of the following domains or motifs:
a) a cAMP phosphorylation site;
b) a tyrosine phosphorylation site;
c) an RNA binding motif;
d) a serine-arginine rich domain; and
e) an LXXLL motif.

### Claim 5

An isolated nucleic acid molecule at least 15 nucleotides in length which hybridizes to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:4.

### Claim 6

An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:4 or a nucleotide sequence which is at least about 60% homologous to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:4.

### Claim 7

An isolated nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 or an amino acid sequence which is at least about 60% homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5.

### Claim 8

An isolated nucleic acid molecule encoding a PGC-1 fusion protein.

### Claim 9 (depends on 1)

An isolated nucleic acid molecule which is antisense to the nucleic acid molecule of claim 1.

### Claim 10

A vector comprising a nucleotide sequence encoding PGC-1.

### Claim 11 (depends on 10)

A host cell containing the vector of claim 10.

### Claim 12 (depends on 11)

A method for producing PGC-1 comprising culturing the host cell of claim 11 in a suitable medium until PGC-1 is produced.

### Claim 13

An isolated PGC-1 protein or a portion thereof which can modulate one or more of the following biological activities: UCP expression, thermogenesis in adipose cells, differentiation of adipose cells, and insulin sensitivity of adipose cells.

### Claim 14

An isolated protein or a portion thereof which comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 such that the protein or portion thereof maintains the ability to modulate one or more of the following biological activities: UCP expression, thermogenesis in adipose cells, differentiation of adipose cells, and insulin sensitivity of adipose cells.

### Claim 15 (depends on 14)

The isolated protein or portion thereof of claim 14, wherein the portion of the protein comprises one or more of the following domains or motifs:
a) a cAMP phosphorylation site;
b) a tyrosine phosphorylation site;
c) an RNA binding motif;
d) a serine-arginine rich domain; and
e) an LXXLL motif.

### Claim 16

An isolated protein comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 or an amino acid sequence which is at least about 60% homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5.

### Claim 17

A fusion protein comprising a PGC-1 polypeptide operatively linked to a non-PGC-1 polypeptide.

### Claim 18

An antigenic peptide of PGC-1 comprising at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:5, the peptide comprising an epitope of PGC-1 such that an antibody raised against the peptide forms a specific immune complex with PGC-1.

### Claim 19

An antibody that specifically binds PGC-1.

### Claim 20

A method for detecting the presence of PGC-1 in a biological sample comprising contacting a biological sample with an agent capable of detecting PGC-1 protein or mRNA.

### Claim 21

A kit for detecting the presence of PGC-1 in a biological sample comprising a labeled or labelable agent capable of detecting PGC-1 protein or mRNA in a biological sample; means for determining the amount of PGC-1 in the sample; and means for comparing the amount of PGC-1 in the sample with a standard.

### Claim 22

A method for identifying a compound capable of treating a disorder characterized by aberrant PGC-1 nucleic acid expression or PGC-1 protein activity comprising assaying the ability of the compound or agent to modulate the expression of PGC-1 nucleic acid or the activity of the PGC-1 protein thereby identifying a compound capable of treating a disorder characterized by aberrant PGC-1 nucleic acid expression or PGC-1 protein activity.

### Claim 23

A method for identifying a compound which binds to PGC-1 protein comprising contacting the PGC-1 protein with the compound under conditions which allow binding of the compound to the PGC-1 protein to form a complex; and detecting the formation of a complex of the PGC-1 protein and the compound in which the ability of the compound to bind to the PGC-1 protein is indicated by the presence of the compound in the complex.

### Claim 24

A method for identifying a compound which inhibits the interaction of the PGC-1 protein with a target molecule comprising contacting, in the presence of the compound, the PGC-1 protein and the target molecule under conditions which allow binding of the target molecule to the PGC-1 protein to form a complex; and detecting the formation of a complex of the PGC-1 protein and the target molecule in which the ability of the compound to inhibit interaction between the PGC-1 protein and the target molecule is indicated by a decrease in complex formation as compared to the amount of complex formed in the absence of the compound.
